AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00810472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLA Matching
Description: HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
Study NCT00810472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Description: Corneal transplantation.
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol
Description: Administered IV.
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered IV.
Study NCT00810472 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Penetrating keratoplasty
Description: Corneal transplantation.
Study NCT03039192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Intranasal esketamine solution 84 milligram (mg)
Study NCT03039192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal Placebo solution
Study NCT03039192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
Study NCT03039192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
Study NCT04037046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening HCV attached onto CCR screening
Description: Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
Study NCT04037046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening HCV attached onto CCR screening by self-testing
Description: Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
Study NCT04037046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV at primary care center
Description: DBS for HCV screening at primary care center
Study NCT00406354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
Study NCT00406354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
Study NCT00387361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: 20 minute post-operative osteopathic manipulation as described in the protocol
Study NCT03586544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
Study NCT03586544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Warm-up exercise
Description: Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
Study NCT01888406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Study NCT01888406 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pure Self-Help
Study NCT02466295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation
Description: I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
Study NCT02466295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Description: I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
Study NCT01512966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
Study NCT04008420 — intervention group
Intervention type: OTHER
Intervention: monitoring of the oxygen reserve index
Description: The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally.
Study NCT04156750 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Administered orally.
Study NCT02529761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study NCT00554801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Audiological testing
Description: Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
Study NCT00554801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological testing
Description: Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
Study NCT00296426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New technology - PAML
Study NCT01712594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Procedure (Medtronic)
Description: The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
Study NCT02241694 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given. Participants are to complete a questionnaire in the study.
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline 200 milligram(mg)
Description: All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline 300 milligram(mg)
Description: In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augment with Memantine
Description: Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose
Study NCT04539951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augment with Aripiprazole
Description: Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose
Study NCT02814825 — intervention group
Intervention type: OTHER
Intervention: ViviGen
Description: ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
Study NCT01890889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ad-Chol-Pre
Study NCT01890889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half-dose Ad-Chol-Pre
Study NCT01890889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Defatted egg yolk without the active ingredient of the other two interventions
Study NCT02529761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study NCT02206841 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
Study NCT02206841 — intervention group
Intervention type: DEVICE
Intervention: ARFI
Description: Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
Study NCT02206841 — intervention group
Intervention type: DEVICE
Intervention: SWE
Description: Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
Study NCT02206841 — intervention group
Intervention type: DEVICE
Intervention: Transient elastography
Description: Transient elastography will be performed for evaluate fibrosis of liver.
Study NCT01883791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: See above Arm description.
Study NCT01883791 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: See Arm Description.
Study NCT04386109 — intervention group
Intervention type: OTHER
Intervention: No intervention - exposure is to COVID-19
Description: No intervention - exposure is to COVID-19
Study NCT05659329 — intervention group
Intervention type: DEVICE
Intervention: Simplex HV
Description: Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
Study NCT03966950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
Study NCT03966950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
Study NCT04372784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
Study NCT04372784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy with Balloon Dilatation
Description: This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
Study NCT04372784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy with Balloon Dilatation
Description: This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
Study NCT03314363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood gas analysis under citrate predilution
Description: blood gas analysis of blood on different sample points and dialysis fluid
Study NCT03314363 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: filter replacement
Description: Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
Study NCT03314363 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IC
Description: monitor patients during the whole study period with indirect calorimetry
Study NCT03314363 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NaCl predilution
Description: Replace citrate predilution with NaCl
Study NCT02529761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response.
Study NCT01695057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT01695057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT01695057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01068041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
Study NCT01068041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
Study NCT02387749 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
Study NCT02371135 — intervention group
Intervention type: GENETIC
Intervention: colonic biopsies
Study NCT03850067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011
Study NCT03850067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT03850067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT02371135 — intervention group
Intervention type: GENETIC
Intervention: questionnaires
Study NCT02787967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 35/4µg NEXThaler®
Description: 4 (four) inhalations (total dose: BDP/FF 140/16 µg)
Study NCT02787967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: free comb. beclomethasone DPI and formoterol DPI
Description: 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
Study NCT02357784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurometer
Description: The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
Study NCT00633438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
Study NCT00633438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
Study NCT00032019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW >70 kg) sub Q injection Day 6 until ANC > 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
Study NCT00032019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
Study NCT00032019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
Study NCT00032019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
Study NCT00032019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
Study NCT00032019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sq m PO bid days 1-5 of ea cycle
Study NCT02882646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ADLER
Description: Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
Study NCT02156635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT00032019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
Study NCT01259752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression stockings
Description: compression stockings
Study NCT02156635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Study NCT02156635 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Study NCT01259752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard non compressive stockings
Description: standard non compressive stockings
Study NCT02709434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational programme
Description: Activity diary analysis and a structured programme of intervention